Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Myelodysplastic Syndrome With Isolated Del(5q)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Previously Treated Myelodysplastic SyndromesRecurrent Adult Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT00839982
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 115
- Registration Number
- NCT00840177
- Locations
- 🇺🇸
Cancer Center of Kansas-Independence, Independence, Kansas, United States
🇺🇸Genesee Hematology Oncology PC, Flint, Michigan, United States
🇺🇸Southeastern Medical Oncology Center-Jacksonville, Jacksonville, North Carolina, United States
Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia
- Conditions
- LeukemiaMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2009-02-06
- Last Posted Date
- 2012-07-20
- Lead Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Target Recruit Count
- 114
- Registration Number
- NCT00838240
- Locations
- 🇧🇪
Institut Jules Bordet, Brussel, Belgium
🇮🇹Azienda Ospedallera Universitaria - Policlinico Tor Vergata, Roma, Italy
🇮🇹Univesita Degli Studi "La Sapienza", Roma, Italy
Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)
- Conditions
- Myelodysplastic SyndromeAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2009-01-29
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Target Recruit Count
- 51
- Registration Number
- NCT00831766
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Cleveland Clinic - Taussig Cancer Institute, Cleveland, Ohio, United States
Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia
- First Posted Date
- 2008-12-09
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 180
- Registration Number
- NCT00804856
- Locations
- 🇫🇷
HOP Edouard Herriot, Lyon Cedex 03, France
🇨🇦Montreal General Hospital - McGill University Health Centre, Montreal, Quebec, Canada
🇫🇷HOP Clémenceau, Hémato, Caen, Caen, France
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- Conditions
- Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1Myelodysplastic Syndrome With Excess Blastst(8;21)High Risk Myelodysplastic SyndromeInv(16)t(16;16)Untreated Adult Acute Myeloid Leukemiade Novo Myelodysplastic Syndrome
- Interventions
- Drug: CytarabineDrug: DecitabineBiological: Filgrastim-sndzDrug: Fludarabine PhosphateDrug: Gemtuzumab OzogamicinDrug: IdarubicinOther: Laboratory Biomarker Analysis
- First Posted Date
- 2008-12-03
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 270
- Registration Number
- NCT00801489
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic SyndromeAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Pure Erythroid Leukemia (M6b)Secondary Acute Myeloid LeukemiaUntreated Adult Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Interventions
- Drug: alvocidibDrug: mitoxantrone hydrochlorideDrug: cytarabineOther: pharmacological studyOther: laboratory biomarker analysis
- First Posted Date
- 2008-11-21
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 78
- Registration Number
- NCT00795002
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia
- Conditions
- Acute Lymphoblastic LeukemiaAdult B Acute Lymphoblastic LeukemiaAdult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1Adult L1 Acute Lymphoblastic LeukemiaAdult L2 Acute Lymphoblastic LeukemiaAdult T Acute Lymphoblastic LeukemiaRecurrent Adult Acute Lymphoblastic Leukemia
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationDrug: CyclophosphamideDrug: CytarabineDrug: DasatinibDrug: DexamethasoneDrug: Doxorubicin HydrochlorideDrug: EtoposideBiological: FilgrastimOther: Laboratory Biomarker AnalysisDrug: Leucovorin CalciumDrug: MethotrexateDrug: MethylprednisoloneProcedure: Peripheral Blood Stem Cell TransplantationDrug: PrednisoneDrug: SirolimusDrug: TacrolimusRadiation: Total-Body IrradiationDrug: Vincristine Sulfate
- First Posted Date
- 2008-11-18
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 97
- Registration Number
- NCT00792948
- Locations
- 🇺🇸
Cancer Center of Kansas-Kingman, Kingman, Kansas, United States
🇺🇸Lawrence Memorial Hospital, Lawrence, Kansas, United States
🇺🇸Southwest Medical Center, Liberal, Kansas, United States
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2008-11-11
- Last Posted Date
- 2018-01-12
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 126
- Registration Number
- NCT00788892
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸North Shore University Hospital, Manhasset, New York, United States
🇺🇸Arizona Cancer Center, Tucson, Arizona, United States
Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic Syndrome
- Interventions
- First Posted Date
- 2008-10-23
- Last Posted Date
- 2016-07-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 122
- Registration Number
- NCT00778375
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.